Komori
Other Disclosures4888STELLA PHARMA CORPORATIONPharmaceuticals

Notice of approval for a partial change to Steboronin’s manufacturing and marketing authorization for recurrent meningioma: approved as Japan’s first drug indicated for recurrent meningioma

Approval was obtained for a partial change to Steboronin’s manufacturing and marketing authorization to add recurrent meningioma as an indication. This makes BNCT treatment for recurrent meningioma an approved treatment.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Steboronin® intravenous infusion bag 9,000 mg/300 mL; boron neutron capture therapy (BNCT)
Applicable field (uses covered by this announcement)

Recurrent meningioma, particularly treatment with BNCT. The clinical trial enrolled patients with recurrent high-grade meningioma (WHO grade 2 or 3).

Launch dateReimbursement coverage is expected to begin on 1 March 2027.
What the company reported numerically
Quantitative Effects

Median progression-free survival: 14.4 months in the investigational treatment group receiving BNCT versus 1.4 months in the control group. The difference was statistically significant.

Relationship between the counterparty and the company
STELLA PHARMA CORPORATION4888
Relationship with the Company

The results of the physician-initiated clinical trial conducted at Osaka Medical and Pharmaceutical University, among other information, formed the basis for the application for approval.

CounterpartyOsaka Medical and Pharmaceutical University

Institution conducting the physician-initiated clinical trial. Other details, including location, representative, business activities, capital and year established, are Not disclosed.

Award/certification name

Designation as an orphan drug; priority review product

Impact on Business Performance

The impact on results for the fiscal year ending March 2027 is expected to be minor. Over the medium to long term, the company expects this to contribute to growth in its BNCT business.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Physician-initiated clinical trial (Phase II randomized controlled trial); support from the Japan Agency for Medical Research and Development (AMED)

Announced details
ItemDetails
Names of Products / Services CoveredSteboronin® intravenous infusion bag 9,000 mg/300 mL; boron neutron capture therapy (BNCT)
CounterpartyOsaka Medical and Pharmaceutical University
Counterparty overviewInstitution conducting the physician-initiated clinical trial. Other details, including location, representative, business activities, capital and year established, are Not disclosed.
Relationship with the CompanyThe results of the physician-initiated clinical trial conducted at Osaka Medical and Pharmaceutical University, among other information, formed the basis for the application for approval.
Launch dateReimbursement coverage is expected to begin on 1 March 2027.
Applicable areaRecurrent meningioma, particularly treatment with BNCT. The clinical trial enrolled patients with recurrent high-grade meningioma (WHO grade 2 or 3).
Award/certification nameDesignation as an orphan drug; priority review product
Quantitative EffectsMedian progression-free survival: 14.4 months in the investigational treatment group receiving BNCT versus 1.4 months in the control group. The difference was statistically significant.
Impact on Business PerformanceThe impact on results for the fiscal year ending March 2027 is expected to be minor. Over the medium to long term, the company expects this to contribute to growth in its BNCT business.
SourcePhysician-initiated clinical trial (Phase II randomized controlled trial); support from the Japan Agency for Medical Research and Development (AMED)
Items this document does not state (8)
Contract ValueOffering priceContract DateAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Recurrent meningioma can be difficult to treat with repeat surgery or re-irradiation, and treatment options had been limited because no drug therapy had previously been approved in Japan. The approval was also based on the statistically significant difference observed in a physician-initiated clinical trial, in which median progression-free survival was 14.4 months in the BNCT group versus 1.4 months in the control group.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of approval for a partial change to Steboronin’s manufacturing and marketing authorization for recurrent meningioma: approved as Japan’s first drug indicated for recurrent meningioma | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori